Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: Nuclear factor-κB pathway as a potential therapeutic target

Cancer Science

Volumn 98, Issue 9, 2007, Pages 1281-1287

  Chuang, Huai Chia ^a,c   Lay, Jong Ding ^a,b   Hsieh, Wen Chuan ^a   Su, Ih Jen ^a,c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b National Taichung Nursing College   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD150 ANTIGEN; CYCLOSPORIN A; ETOPOSIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; ROSIGLITAZONE; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

APOPTOSIS; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TREATMENT FAILURE; EPSTEIN BARR VIRUS; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MOLECULAR MECHANICS; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELAPSE; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT; UPREGULATION; VIRUS CELL INTERACTION; VIRUS INFECTION;

ANIMALS; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; LYMPHOMA, T-CELL; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 34547842304     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00549.x     Document Type: Review

References (80)

1. Scott RB, Robb-Smith AHT. Histiocytic medullary reticulosis. Lancet 1939; ii: 194-8.
2. Robb-Smith AH. Before our time: Half a century of histiocytic medullary reticulosis: A T-cell teaser? Histopathology 1990; 17: 279-83.
3. Warthin AS. The general neoplastic relationship of Hodgkin's disease, aleukemic and leukemic lymphoid lymphosarcoma. Ann Surg 1931; 93: 153-61.
4. Rappaport H. The clinical and biologic significance of recent observations concerning the spread of Hodgkin's disease. Rev Fr Etud Clin Biol 1969; 14: 449-50.
5. Robb-Smith AH. Letter: Immuno-topography of lymphoreticular disorders. Lancet 1974; 1: 513-14.
6. Gatter KCCL. Oakley lecture (1989). Diagnostic immunocytochemistry: achievements and challenges. J Pathol 1989; 159: 183-90.
7. Isaacson P, Wright DH. Malignant histiocytosis of the intestine. Its relationship to malabsorption and ulcerative jejunitis. Hum Pathol 1978; 9: 661-77.
8. Stein H, Mason DY, Gerdes J et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848-58.
9. Risdall RJ, McKenna RW, Nesbit ME et al. Virus associated hemophagocytic syndrome: A benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 1979; 44: 993-1002.
10. Brown RE, Bowman WP, D'Cruz CA, Pick TE, Champion JE. Endoperoxidation, hyperprostaglandinemia, and hyperlipidemia in a case of erythrophagocytic lymphohistiocytosis. Reversal with VP-16 and indomethacin. Cancer 1987; 60: 2388-93.
11. Watanabe S, Furuya T, Tsunematsu Y. Outline of proliferative disorders in the mononuclear phagocytic system - familial hemophagocytic reticulosis, familial erythrophagocytic lymphohistiocytosis. Nippon Rinsho 1989; 47: 616-20.
12. Su IJ, Hsieh HJ, Lee CY. Histiocytic medullary reticulosis: A lethal form of primary EBV infection in young children in Taiwan. Lancet 1989; 1: 389.
13. Kawaguchi H, Miyashita T, Herbst H et al. Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome. J Clin Invest 1993; 92: 1444-50.
14. Ebihara T, Sakai N, Koyama S. CD8+ T cell subsets of cytotoxic T lymphocytes induced by Epstein-Barr virus infection in infectious mononucleosis. Tohoku J Exp Med 1990; 162: 213-24.
15. Rickinson AB. Epstein-Barr virus in action in vivo. N Engl J Med 1998; 338: 1461-3.
16. Yoneda N, Tatsumi E, Kawanishi M et al. Detection of Epstein-Barr virus genome in benign polyclonal proliferative T cells of a young male patient. Blood 1990; 76: 172-7.
17. Chan LC, Srivastava G, Pittaluga S, Kwong YL, Liu HW, Yuen HL. Detection of clonal Epstein-Barr virus in malignant proliferation of peripheral blood CD3+ CD8+ T cells. Leukemia 1992; 6: 952-6.
18. Su IJ, Chen RL, Lin DT, Lin KS, Chen CC. Epstein-Barr virus (EBV) infects T lymphocytes in childhood EBV-associated hemophagocytic syndrome in Taiwan. Am J Pathol 1994; 144: 1219-25.
19. Kimura H, Hoshino Y, Kanegane H et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001;98: 280-6.
20. Kasahara Y, Yachie A, Takei K et al. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 2001; 98: 1882-8.
21. Masucci MG, Szigeti R, Ernberg I et al. Cellular immune defects to Epstein-Barr virus-determined antigens in young males. Cancer Res 1981; 41: 4284-91.
22. Coffey AJ, Brooksbank RA, Brandau O et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 1998; 20: 129-35.
23. Sayos J, Wu C, Morra M et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998; 395: 462-9.
24. Grosieux C, Amoric JC, Mechinaud F et al. Cutaneous and neurologic vasculitis disclosing EBV-selective immunodeficiency. Ann Dermatol Venereol 1996; 123: 387-92.
25. Jager M, Benninger-Doring G, Prang N et al. Epstein-Barr virus-infected B cells of males with the X-linked lymphoproliferative syndrome stimulate and are susceptible to T-cell-mediated lysis. Int J Cancer 1998; 76: 694-701.
26. Malbran A, Belmonte L, Ruibal-Ares B, Bare P, Bracco MM. X-linked lymphoproliferative syndrome, EBV virus infection and defects in cytotoxicity lymphocyte regulation. Medicina (B Aires) 2003; 63: 70-6.
27. Sharifi R, Sinclair JC, Gilmour KC et al. SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease. Blood 2004; 103: 3821-7.
28. Stepp SE, Dufourcq-Lagelouse R, Le Deist F et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286: 1957-9.
29. Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood 2002; 99: 61-6.
30. Feldmann J, Callebaut I, Raposo G et al. Munc 13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 2003; 115: 461-73.
31. Ma X, Okamura A, Yosioka M, Ishiguro N, Kikuta H, Kobayashi K. No mutations of SAP/SH2D1A/DSHP and perforin genes in patients with Epstein-Barr virus-associated hemophagocytic syndrome in Japan. J Med Virol 2001; 65: 358-61.
32. Ohga S, Matsuzaki A, Nishizaki M et al. Inflammatory cytokines in virus-associated hemophagocytic syndrome. Interferon-gamma as a sensitive indicator of disease activity. Am J Pediatr Hematol Oncol 1993; 15: 291-8.
33. Su IJ, Wang CH, Cheng AL, Chen RL. Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders. disease spectrum, pathogenesis, and management. Leuk Lymphoma 1995; 19: 401-6.
34. Jones JF, Shurin S, Abramowsky C et al. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med 1988; 318: 733-41.
35. Chen JS, Lin KH, Lin DT, Chen RL, Jou ST, Su IJ. Longitudinal observation and outcome of nonfamilial childhood haemophagocytic syndrome receiving etoposide-containing regimens. Br J Haematol 1998; 103: 756-62.
36. Fujisaki T, Nagafuchi S, Niho Y, Tsuneyoshi M, Oshima K, Kikuchi M. Malignant histiocytosis in a patient with chronic active Epstein-Barr virus infection. Lancet 1992; 340: 1168-9.
37. Su IJ, Hsu YH, Lin MT, Cheng AL, Wang CH, Weiss LM. Epstein-Barr virus-containing T-cell lymphoma presents with hemophagocytic syndrome mimicking malignant histiocytosis. Cancer 1993; 72: 2019-27.
38. Kanegane H, Bhatia K, Gutierrez M et al. A syndrome of peripheral blood T-cell infection with Epstein-Barr virus (EBV) followed by EBV-positive T-cell lymphoma. Blood 1998; 91: 2085-91.
39. Pikarsky E, Porat RM, Stein I et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-6.
40. Mori N, Yamada Y, Ikeda S et al. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 2002; 100: 1828-34.
41. Inoue J, Gohda J, Akiyama T, Semba K. NF-kappaB activation in development and progression of cancer. Cancer Sci 2007; 98: 268-74.
42. Chen RL, Su IJ, Lin KH et al. Fulminant childhood hemophagocytic syndrome mimicking histiocytic medullary reticulosis. An atypical form of Epstein-Barr virus infection. Am J Clin Pathol 1991; 96: 171-6.
43. Foss HD, Herbst H, Hummel M et al. Patterns of cytokine gene expression in infectious mononucleosis. Blood 1994; 83: 707-12.
44. Feingold KR, Soued M, Staprans I et al. Effect of tumor necrosis factor (TNF) on lipid metabolism in the diabetic rat. Evidence that inhibition of adipose tissue lipoprotein lipase activity is not required for TNF-induced hyperlipidemia. J Clin Invest 1989; 83: 1116-21.
45. Mizuhara H, O'Neill E, Seki N et al. T cell activation-associated hepatic injury: Mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 1994; 179: 1529-37.
46. Yao M, Cheng AL, Su IJ et al. Clinicopathological spectrum of haemophagocytic syndrome in Epstein-Barr virus-associated peripheral T-cell lymphoma. Br J Haematol 1994; 87: 535-43.
47. Falini B, Pileri S, De Solas I et al. Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood 1990; 75: 434-44.
48. Lay JD, Tsao CJ, Chen JY, Kadin ME, Su IJ. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest 1997; 100: 1969-79.
49. Akashi K, Hayashi S, Gondo H et al. Involvement of interferon-gamma and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults. Br J Haematol 1994; 87: 243-50.
50. Rusten LS, Jacobsen FW, Lesslauer W, Loetscher H, Smeland EB, Jacobsen SE. Bifunctional effects of tumor necrosis factor alpha (TNF alpha) on the growth of mature and primitive human hematopoietic progenitor cells: involvement of p55 and p75 TNF receptors. Blood 1994; 83: 3152-9.
51. Gosselin J, Flamand L, D'Addario M et al. Modulatory effects of Epstein-Barr, herpes simplex, and human herpes-6 viral infections and coinfections on cytokine synthesis. A comparative study. J Immunol 1992; 149: 181-7.
52. Henter JI, Carlson LA, Soder O, Nilsson-Ehle P, Elinder G. Lipoprotein alterations and plasma lipoprotein lipase reduction in familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand 1991; 80: 675-81.
53. Henter JI, Elinder G, Soder O, Hansson M, Andersson B, Andersson U. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 1991; 78: 2918-22.
54. Brown HG. Patient issues in breast reconstruction. Cancer 1991; 68: 1167-9.
55. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol 2002; 44: 259-72.
56. Imashuku S, Hibi S, Fujiwara F, Ikushima S, Todo S. Haemophagocytic lymphohistiocytosis, interferon-gamma-anemia and Epstein-Barr virus involvement. Br J Haematol 1994;88: 656-8.
57. Takada K, Komano J, Imai S. The role of Epstein-Barr virus in oncogenesis. Tanpakushitsu Kakusan Koso 1999; 44: 2565-74.
58. Thorley-Lawson DA. Epstein-Barr virus: Exploiting the immune system. Nat Rev Immunol 2001; 1: 75-82.
59. Imai S, Sugiura M, Oikawa O et al. Epstein-Barr virus (EBV)-carrying and -expressing T-cell lines established from severe chronic active EBV infection. Blood 1996; 87: 1446-57.
60. Lay JD, Chuang SE, Rowe M, Su IJ. Epstein-Barr virus latent membrane protein-1 mediates upregulation of tumor necrosis factor-alpha in EBV-infected T cells. implications for the pathogenesis of hemophagocytic syndrome. J Biomed Sci 2003; 10: 146-55.
61. Chuang HC, Lay JD, Hsieh WC et al. Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome. Blood 2005; 106: 3090-6.
62. Chuang HC, Lay JD, Chuang SE, Hsieh WC, Chang Y, Su IJ. Survival of LMP1-expressed T cells from TNF-alpha-induced apoptosis: A molecular mechanism of the hemophagocytic syndrome to T cell lymphoma. Am J Pathol 2007; 170: 1607-17.
63. Morrison TE, Mauser A, Klingelhutz A, Kenney SC. Epstein-Barr virus immediate-early protein BZLF1 inhibits tumor necrosis factor alpha-induced signaling and apoptosis by downregulating tumor necrosis factor receptor 1. J Virol 2004; 78: 544-9.
64. Geleziunas R, Xu W, Takeda K, Ichijo H, Greene WC. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature 2001; 410: 834-8.
65. Xu XN, Screaton G. HIV-1 Nef: Negative effector of Fas? Nat Immunol 2001; 2: 384-5.
66. Suzumiya J, Ohshima K, Takeshita M et al. Nasal lymphomas in Japan: A high prevalence of Epstein-Barr virus type A and deletion within the latent membrane protein gene. Leuk Lymphoma 1999; 35: 567-78.
67. Su IJ, Chen JY. The role of Epstein-Barr virus in lymphoid malignancies. Crit Rev Oncol Hematol 1997; 26: 25-41.
68. Su IJ, Hsieh HC, Lin KH et al. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: A clinicopathologic and molecular analysis. Blood 1991; 77: 799-808.
69. Obama K, Tara M, Niina K. 1-asparaginase induced complete remission in Epstein-Barr virus positive, multidrug resistant, cutaneous T-cell lymphoma. Int J Hematol 1999; 69: 260-2.
70. Kaizu K, Maeda M, Ohkawa T et al. Marked elevation of soluble fas ligand and cytokine secretion after splenectomy in aggressive natural killer cell leukemia/lymphoma. Leuk Lymphoma 2004; 45: 2291-4.
71. Chen JS, Tzeng CC, Tsao CJ et al. Clonal karyotype abnormalities in EBV-associated hemophagocytic syndrome. Haematologica 1997; 82: 572-6.
72. Jung CK, Lee KY, Kim Y et al. Epstein-Barr virus infection, drug resistance and prognosis in Korean T- and NK-cell lymphomas. Pathol Int 2001; 51: 355-63.
73. Dupuis J, Emile JF, Mounier N et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood 2006; 108: 4163-9.
74. Hayashi K, Ohara N, Teramoto N et al. An animal model for human EBV-associated hemophagocytic syndrome: Herpesvirus papio frequently induces fatal lymphoproliferative disorders with hemophagocytic syndrome in rabbits. Am J Pathol 2001; 158: 1533-42.
75. Hsieh WC, Chen CR, Lin YH, Hayashi K, Su IJ. Emergence of heterophile antibodies precipitates phagocytosis of red cells by macrophages in EBV-associated hemophagocytic syndrome. Am J Pathol 2007; 170: 1629-39.
76. Hayashi K, Teramoto N, Akagi T. Animal in vivo models of EBV-associated lymphoproliferative diseases: Special references to rabbit models. Histol Histopathol 2002; 17: 1293-310.
77. Imashuku S, Teramura T, Kuriyama K et al. Risk of etoposide-related acute myeloid leukemia in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Int J Hematol 2002; 75: 174-7.
78. Minegishi M, Ohashi Y, Kumaki S et al. Successful umbilical cord blood transplantation from an unrelated donor for a patient with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Bone Marrow Transplant 2001; 27: 883-6.
79. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002; 2: 748-59.
80. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004; 5: 419-29.